ATLANTA, April 26, 2017 /PRNewswire/ --
First Quarter Highlights:
- Revenues Increased Five Percent Year-over-Year to $45.1 Million; Non-GAAP Revenues Increased Five Percent Year-over-Year
- Gross Margins were 65 Percent; Non-GAAP Gross Margins were 70 Percent
- GAAP Net Income was $2.2 Million, or $0.06 Per Fully Diluted Common Share; Non-GAAP Net Income was $3.2 Million, or $0.09 Per Fully Diluted Common Share
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac surgery, announced today its results for the first quarter of 2017.
J. Patrick Mackin, Chairman, President, and Chief Executive Officer, said, “We are very pleased with the many positive factors that contributed to our successful first quarter. We made considerable progress on the items that impacted our prior quarter and we continue to benefit from our decision to focus on select markets. We posted solid first quarter financial results driven by our On-X and tissue products. Non-GAAP On-X revenues were up 12 percent excluding the OEM business. Our tissue processing business was strong as revenues increased 10 percent year-over-year due to robust demand for our cardiac tissues and our increased focus on re-engaging vascular tissue customers. Our growth in medical device and tissue processing revenues contributed to non-GAAP gross margin of 70 percent. Given our strong performance in the first quarter, we remain confident in our ability to achieve our 2017 strategic and financial goals.”
Revenues for the first quarter of 2017 increased five percent to $45.1 million, compared to $43.0 million for the first quarter of 2016. The increase was primarily driven by increases in On-X and tissue processing revenues, partially offset by the absence of HeRO and ProCol revenues, and a decrease in TMR revenues. Non-GAAP revenues for the first quarter of 2017 increased five percent compared to the first quarter of 2016. A reconciliation of GAAP to non-GAAP financial metrics is included as part of this press release.
GAAP net income for the first quarter of 2017 was $2.2 million, or $0.06 per fully diluted common share, compared to net income of $2.5 million, or $0.08 per fully diluted common share, for the first quarter of 2016. Non-GAAP net income for the first quarter of 2017 was $3.2 million, or $0.09 per fully diluted common share, compared to non-GAAP net income of $3.2 million, or $0.10 per fully diluted common share for the first quarter of 2016.
With the exception of our income tax rate, the Company is reiterating its full year 2017 financial guidance, as summarized below, and expects revenues in the second quarter of 2017 to be between $46.5 million and $47.0 million.
2017 Financial Guidance Summary | |
Total revenues | $188 Million - $192 Million |
Product revenues | Year-over-year mid-single digits % non-GAAP revenue increase |
Tissue processing revenues | Year-over-year mid-single digits % revenue increase |
Gross margins | Between 68% - 69% |
R&D expenses | $17.0 Million - $19.0 Million |
Income tax rate | Mid to Upper 20% |
Non-GAAP income per common share | $0.40 - $0.43 |
All numbers in the table above are GAAP except where expressly referenced as non-GAAP. The Company does not provide GAAP income per common share on a forward-looking basis because the Company is unable to predict with reasonable certainty business development and acquisition-related expenses, purchase accounting fair value adjustments, and any unusual gains and losses without unreasonable effort. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP.
The Company’s financial guidance for 2017 is subject to the risks identified below.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company’s non-GAAP revenues include (as applicable) On-X revenues for the period in 2016 prior to the closing of the acquisition and excludes revenues for the HeRO Graft and ProCol product lines for 2016. The Company’s other non-GAAP results exclude (as applicable) business development expenses; gain on sale of business components; amortization expenses; and inventory basis step-up expense. The Company believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions and the operating expense structure of the Company’s existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses and the transaction and integration expenses incurred in connection with recently acquired and divested product lines. The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as new acquisitions, or non-cash expense related to amortization of previously acquired tangible and intangible assets. The Company does, however, expect to incur similar types of expenses in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur.
Webcast and Conference Call Information
The Company will hold a teleconference call and live webcast tomorrow at 8:00 a.m. Eastern Time to discuss the results followed by a question and answer session hosted by Mr. Mackin.
To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 8:00 a.m. A replay of the teleconference will be available April 27 through May 3 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13659245.
The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife website at www.cryolife.com and selecting the heading Webcasts & Presentations.
About CryoLife, Inc.
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac surgical procedures. CryoLife markets and sells products in more than 80 countries worldwide. For additional information about CryoLife, visit our website, www.cryolife.com.
Statements made in this press release that look forward in time or that express management’s beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include those regarding our financial guidance for 2017, the benefits from our decision to focus on select markets on our 2017 results and beyond and our confidence in our ability to achieve our 2017 strategic and financial goals. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations.
To read full press release, please click here.
